Wow so In this study one of many has the severe critical mortality rate at 35.8%. Based off conference call number that was given 87 of 390 with still about a week for good handful of patients to hit 28th day currently at 22% mortality rate. Could go up to 23% with 90 deaths as a couple more deaths should be expected.

If all patients were given leronlimab and it just compared to SOC leronlimab trial #’s would already have significant reduction in mortality. 22% vs 36%. Now take into account 130 of the 390 did not receive leronlimab its easy to give that group min 31% mortality rate which would be min 40 ..... 40/130 =31% then 50 would be in leronlimab arm 50/260 = 19% that look like a 50% reduction in mortality using those numbers and they actually align with the survival rates of all of our EIND patients I believe that was around 18% mortality or 82% survival rate. I’m feeling really good about CYDY I own well more than a originally intended to but I will be buying more Tom after I shift some things around, this is just too great of a stock to not maximize potential on. The writing and the Paint is on the wall, just waiting for it to dry.